Evidence map›Paper›PMID 28112324›Full record

ArticleMolecular bioSystems2017

Inference of cancer mechanisms through computational systems analysis.

Zhen Qi, Eberhard O Voit

Abstract read
In one paragraph

Article in Molecular bioSystems, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Perspective: Dimensions of the scientific method.PLoS computational biology · 2019
    Article
  3. Dynamical systems approaches to personalized medicine.Current opinion in biotechnology · 2019
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhen QiDepartment of Biomedical Engineering, Georgia Institute of Technology and Emory University Medical School, 950 Atlantic Drive NW, Atlanta, GA 30332-2000, USA. zhen.qi@gatech.edu.ORCID http://orcid.org/0000-0003-1822-6975
Eberhard O VoitDepartment of Biomedical Engineering, Georgia Institute of Technology and Emory University Medical School, 950 Atlantic Drive NW, Atlanta, GA 30332-2000, USA. zhen.qi@gatech.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Pilot Project ProgramP30ES019776 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2013 to 2026
$22.6M
SAMPLE COREU24DK097215 · NIDDK · UNIVERSITY OF KENTUCKY · PI FAN, TERESA WHEI-MEI, HIGASHI, RICHARD M · 2013 to 2017
$8.7M
PROJECT 3: METABOLOMIC BIOMARKERS OF PARKINSON'S DISEASEP01ES016731 · NIEHS · EMORY UNIVERSITY · PI MILLER, GARY W · 2008 to 2012
$6.7M
NIAID NIH HHS HHSN272201200031CNIDDK NIH HHS U24 DK097215NIEHS NIH HHS P01 ES016731NIEHS NIH HHS P30 ES019776NIH HHS P51 OD011132
6 · The paper itself

Abstract

Large amounts of metabolomics data have been accumulated to study metabolic alterations in cancer that allow cancer cells to synthesize molecular materials necessary for cell growth and proliferation. Although metabolic reprogramming in cancer was discovered almost a century ago, the underlying biochemical mechanisms are still unclear. We show that metabolomics data can be used to infer likely biochemical mechanisms associated with cancer. The proposed inference method is data-driven and quite generic; its efficacy is demonstrated by the analysis of changes in purine metabolism of human renal cell carcinoma. The method and results are essentially unbiased and tolerate noise in the data well. The proposed method correctly identified and accurately quantified primary enzymatic alterations in cancer, and these account for over 80% of the metabolic alterations in the investigated carcinoma. Interestingly, the two primary action sites are not the most sensitive reaction steps in purine metabolism, which implies that sensitivity analysis is not a valid approach for identifying cancer targets. The proposed method exhibits statistically high precision and robustness even for analyses of moderately incomplete metabolomics data. By permitting analyses of individual metabolic profiles, the method may become a tool of personalized precision medicine.

Indexed as

Models, BiologicalAlgorithmsComputational BiologyHumansMetabolic Networks and PathwaysMetabolomeMetabolomicsNeoplasmsSystems Biology

Identifiers

PMID28112324
PMCPMC5330810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.